Glenmede Trust CO Na Mirati Therapeutics, Inc. Transaction History

Glenmede Trust CO Na

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $1,620 - $2,402	-10 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $720 - $1,203	10 New	10 $1,000
Q4 2019 Feb 12, 2020	SELL	$70.76 - $128.86 $5,307 - $9,664	-75 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $111,021 - $156,180	-1,425 Reduced 95.0%	75 $5,000
Q2 2019 Aug 13, 2019	BUY	$59.49 - $104.71 $39,263 - $69,108	660 Added 78.57%	1,500 $154,000
Q1 2019 May 14, 2019	BUY	$43.65 - $78.95 $36,666 - $66,318	840 New	840 $61,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.